Patents by Inventor Weisan Chen

Weisan Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IN VIVO EFFICACY OF NY-ESO-1 PLUS ADJUVANT
    Publication number: 20160000894
    Abstract: The invention relates to the discovery that administration of NY-ESO-1 protein, in combination with a saponin based adjuvant leads to an unexpectedly strong immune response against NY-ESO-1 expressing cells. Preferably, the combination is administered intramuscularly.
    Type: Application
    Filed: April 28, 2015
    Publication date: January 7, 2016
    Applicants: CSL Limited, Ludwig Institute for Cancer Research
    Inventors: Jonathan Cebon, Ian Davis, Weisan Chen, Simon Green
  • Expression of FoxP3 by cancer cells
    Patent number: 8420791
    Abstract: The present invention relates to the treatment, diagnosis, and prophylaxis of cancer based on the expression of foxp3.
    Type: Grant
    Filed: November 27, 2007
    Date of Patent: April 16, 2013
    Assignee: Ludwig Institute for Cancer Research Ltd.
    Inventors: Lisa Michelle Ebert, Weisan Chen, Jonathan S. Cebon, Ian Davis
  • IN VIVO EFFICACY OF NY-ESO-1 PLUS ADJUVANT
    Publication number: 20120171232
    Abstract: The invention relates to the discovery that administration of NY-ESO-1 protein, in combination with a saponin based adjuvant leads to an unexpectedly strong immune response against NY-ESO-1 expressing cells. Preferably, the combination is administered intramuscularly.
    Type: Application
    Filed: May 19, 2011
    Publication date: July 5, 2012
    Inventors: Jonathan Cebon, Ian Davis, Weisan Chen, Simon Green
  • EXPRESSION OF FOXP3 BY CANCER CELLS
    Publication number: 20100143359
    Abstract: The present invention relates to the treatment, diagnosis, and prophylaxis of cancer based on the expression of foxp3.
    Type: Application
    Filed: November 27, 2007
    Publication date: June 10, 2010
    Applicant: Ludwig Institute for Cancer Research Ltd.
    Inventors: Lisa Michelle Ebert, Weisan Chen, Jonathan S. Cebon, Ian Davis
  • In vivo efficacy of ny-eso-1 plus adjuvant
    Publication number: 20070190072
    Abstract: The invention relates to the discovery that administration of NY-ESO-1 protein, in combination with a saponin based adjuvant leads to an unexpectedly strong immune response against NY-ESO-1 expressing cells. Preferably, the combination is administered intramuscularly.
    Type: Application
    Filed: September 30, 2004
    Publication date: August 16, 2007
    Inventors: Jonathan Cebon, Ian Davis, Weisan Chen, Simon Green